# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Hartaj Singh upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Perform to Outperform and announces $180 p...
https://www.statnews.com/2024/05/07/duchenne-muscular-dystrophy-pfizer-gene-therapy-boy-dies/
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target fro...
Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 pri...
Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $166 price target.
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of ...